BioMarin Pharmaceutical Management

Management criteria checks 3/4

BioMarin Pharmaceutical's CEO is Alexander Hardy, appointed in Dec 2023, has a tenure of 1.42 years. total yearly compensation is $14.85M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth CHF3.18M. The average tenure of the management team and the board of directors is 2.2 years and 5 years respectively.

Key information

Alexander Hardy

Chief executive officer

US$14.9m

Total compensation

CEO salary percentage	7.07%
CEO tenure	1.4yrs
CEO ownership	0.03%
Management average tenure	2.2yrs
Board average tenure	5yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Alexander Hardy's remuneration changed compared to BioMarin Pharmaceutical's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2025	n/a	n/a	US$524m
Dec 31 2024	US$15m	US$1m	US$427m
Sep 30 2024	n/a	n/a	US$322m
Jun 30 2024	n/a	n/a	US$257m
Mar 31 2024	n/a	n/a	US$205m
Dec 31 2023	US$19m	US$65k	US$168m

Compensation vs Market: Alexander's total compensation ($USD14.85M) is above average for companies of similar size in the Swiss market ($USD5.03M).

Compensation vs Earnings: Alexander's compensation has been consistent with company performance over the past year.

CEO

Alexander Hardy (55 yo)

1.4yrs

Tenure

US$14,853,605

Compensation

Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023. He had been Chief Executive Officer at Genentech, Inc. since March 1, 20...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Alexander Hardy	President	1.4yrs	US$14.85m	0.033% CHF 3.2m
Brian Mueller	Executive VP of Finance & CFO	5.3yrs	US$5.50m	0.052% CHF 5.0m
George Davis	Executive VP	21.3yrs	US$5.06m	0.043% CHF 4.1m
Cristin Hubbard	Executive VP & Chief Commercial Officer	1yr	US$6.93m	no data
Gregory Friberg	Executive VP and Chief Research & Development Officer	less than a year	US$7.22m	no data
Erin Burkhart	Group VP & Chief Accounting Officer	3yrs	no data	0.0088% CHF 843.2k
C. Guyer	Executive VP & CTO	no data	US$5.70m	0.032% CHF 3.0m
Kevin Eggan	Chief Scientific Officer & Senior VP of Research and Early Development	no data	no data	no data
Amy Wireman	Executive VP & Chief People Officer	6.3yrs	no data	no data
Ganesh Vedantham	Senior Vice President of Technical Development	3.6yrs	no data	no data
Marni Kottle	Executive VP & Chief Corporate Affairs Officer	1.3yrs	no data	no data
James H. Sabry	Executive VP & Chief Business Officer	less than a year	no data	no data

2.2yrs

Average Tenure

54yo

Average Age

Experienced Management: BM8's management team is considered experienced (2.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Alexander Hardy	President	1.4yrs	US$14.85m	0.033% CHF 3.2m
Richard Meier	Independent Chairman of the Board	18.4yrs	US$719.07k	0.059% CHF 5.7m
David E. Pyott	Independent Director	9.3yrs	US$458.05k	0.023% CHF 2.2m
Mark Enyedy	Independent Director	1.4yrs	US$461.17k	0.0011% CHF 108.7k
Elaine Heron	Independent Director	22.8yrs	US$458.55k	0.048% CHF 4.6m
Willard Dere	Independent Director	8.8yrs	US$463.05k	0.014% CHF 1.4m
Timothy Walbert	Independent Director	less than a year	no data	0.00022% CHF 21.0k
Maykin Ho	Independent Director	4.3yrs	US$467.05k	0.0087% CHF 827.9k
Robert Hombach	Independent Director	7.7yrs	US$467.05k	0.016% CHF 1.5m
Athena Countouriotis	Independent Director	1.4yrs	US$445.05k	0.0011% CHF 108.7k
Elizabeth Anderson	Independent Director	5.8yrs	US$463.55k	0.012% CHF 1.1m
Barbara Bodem	Independent Director	1.4yrs	US$461.17k	0.0011% CHF 108.7k

5.0yrs

Average Tenure

62yo

Average Age

Experienced Board: BM8's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 06:19
End of Day Share Price	2025/05/09 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioMarin Pharmaceutical Inc. is covered by 56 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Ishan Majumdar	Baptista Research
Ying Huang	Barclays